TMX Newsfile News Releases (Digital Media Online (DMO)) [health]

Custom Health to Report Third Quarter 2026 Financial Results on November 16, 2026

Fri, 13 Nov 2026 17:18:00 -0500

Custom Health to release third quarter 2026 financial results on November 16, 2026, and will hold a conference call and simultaneous webcast the next day on Tuesday, November 17, 2026, at 11:00 am EST (9:00 am PCT).

Kelowna, British Columbia--(Newsfile Corp. - November 13, 2026) - Custom Health Holdings Inc. (TSX: CHLT) ("Custom Health" or the "Company"), an AI-enabled healthcare technology company building the infrastructure for medication management at home, is pleased to announce the Company will release its Fiscal Third Quarter 2026 financial results for the period ended September 30, 2026, on Monday, November 16, 2026. The Company will hold a conference call and simultaneous webcast to discuss its results on the next day Tuesday, November 17, 2026, at 11:00 am EST (9:00 am PCT). The call will be hosted by Shane Bishop, Chief Executive Officer, and Jason Nalewany, Chief Financial Officer.

Custom Health Third Quarter 2026 Financial Results Conference Call

Date:	Tuesday, November 17, 2026
Time:	11:00 AM EST / 9:00 AM PCT
Webcast link:	https://bit.ly/CHLT-Q3
Toll-Free North America:	(+1) 800 717 1738
Toronto Local and International Toll:	(+1) 289 514 5100

When connecting to the conference call via phone, please dial in 10 minutes prior to the start of the call and ask to be joined into the "Custom Health Holdings Inc. Conference Call."

Shane Bishop
Chief Executive Officer
Custom Health Holdings Inc.

About Custom Health

Custom Health is an AI-enabled healthcare technology company building the infrastructure for medication management at home. The Company connects in-home technology, pharmacy, and pharmacist-led clinicians to create continuous visibility into a patient's medication use and support timely clinical action. Powered by its proprietary AdhereNet® platform, Custom Health operates an integrated pharmacy network across Canada and the U.S. as part of its broader infrastructure, supporting medication delivery, medication-use insights, and pharmacist-led care to enable earlier intervention and better medication management at home. To learn more, visit customhealth.com.

For more information:

Pardeep S. Sangha
Investor Relations, Custom Health
Phone: 604-572-6392
ir@customhealth.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/324022

NuGen Medical Devices Provides Update on Health Canada Licence Application

Fri, 13 Nov 2026 17:15:00 -0500

Toronto, Ontario--(Newsfile Corp. - November 13, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a developer of needle-free drug delivery technology, provides an update regarding its Canadian medical device licence for the InsuJet™ needle-free insulin injection system.

Further to the Company's news release dated February 5, 2026, Health Canada has issued a Notice of Refusal in respect of the Company's Class II medical device licence application no. 407982. As previously disclosed, the Company's prior Canadian medical device licence had lapsed and sales in Canada were halted while the new application was under review. Sales and further supply of InsuJet in Canada remain halted.

Health Canada determined that the clinical evidence submitted with the application was insufficient to demonstrate compliance with certain safety and effectiveness requirements under sections 11, 12 and 13 of the Canadian Medical Devices Regulations. The matters identified by Health Canada include the need for additional evidence concerning insulin-specific clinical performance, bioequivalence or alternatively evidence supporting the safety and effectiveness of insulin therapy using the device, longer-term glycemic control and safety endpoints, reliable patient self-administration, and injection performance.

The Notice of Refusal applies to the Canadian application and does not, by itself, amend the regulatory status of InsuJet in jurisdictions outside Canada. NuGen continues to maintain registrations and commercial activities in a number of markets outside Canada, subject in each case to applicable local regulatory requirements.

The Notice of Refusal does not state that InsuJet is unsafe or ineffective. It states that the evidence submitted was insufficient to demonstrate that the requirements applicable to the Canadian application and its proposed use with NovoRapid insulin had been met. Investors should not interpret this distinction as an assurance that a future Canadian application will be approved.

Canadian Market and Existing Users

Based on discussions with the Company's Canadian regulatory representative, the Notice of Refusal does not require a recall of InsuJet devices previously lawfully imported and sold in Canada while the applicable licence was active. The Company has also been advised that existing Canadian users are not required to discontinue use of devices already supplied.

Clinical Evidence and Regulatory Path Forward

NuGen intends to review the Notice of Refusal with its regulatory and clinical advisers and to continue discussions with Health Canada concerning the evidence that may be required for a future submission. Subject to available funding, final protocol design, regulatory feedback and other factors, the Company currently intends to incorporate relevant elements of Health Canada's feedback into clinical evidence-generation activities in connection with its next-generation needle-free injector platform.

Management Comment

"We are disappointed with Health Canada's decision, but the Notice of Refusal provides greater clarity regarding the additional clinical evidence required for a future Canadian application," said Liang Lin, Chief Executive Officer of NuGen. "We intend to consider these requirements as part of our planned clinical program for our next-generation needle-free technology. While sales and further supply in Canada remain halted, we remain committed to working with our regulatory and clinical partners to address Health Canada's requirements and pursue a path back to the Canadian market."

About NuGen Medical Devices

NuGen develops next-generation needle-free devices for subcutaneous drug delivery. Its flagship InsuJet™ system has been registered in numerous international markets and is designed to provide an alternative to conventional needle-based injections.

Websites: insujet.com | nugenmd.com
Investor Relations: IR@nugenmd.com

For further information, please contact:

Ajay Mishra,

Chief Financial Officer
+1-833-867-5557
ir@nugenmd.com

Notice Regarding Forward-Looking Information:

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accept responsibility for the adequacy or accuracy of this release.

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. These forward-looking statements are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. The forward-looking information contained herein is given as of the date hereof and the Company assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/323903

Cheelcare Announces Results of 2026 Annual General Meeting

Fri, 13 Nov 2026 16:15:00 -0500

Markham, Ontario--(Newsfile Corp. - November 13, 2026) - Cheelcare Inc. (TSXV: CHER) (OTC: CHCRF) ("Cheelcare" or the "Company"), a Canadian innovator in advanced mobility solutions, today announced the results of its Annual General Meeting of Shareholders (the "Meeting") held on November 13, 2026, in Markham, Ontario.

Shareholders approved all matters presented at the Meeting, including fixing the number of directors at six, electing the Company's Board of Directors, appointing the auditor and approving the continuation of the Company's existing stock option plan.

A total of 4,524,452 common shares, representing approximately 19.90% of the Company's issued and outstanding shares, were represented by proxy at the Meeting.

Election of Directors
Shareholders approved fixing the number of directors at six. All six director nominees were elected to serve until the next annual general meeting of shareholders or until their successors are duly elected or appointed.

The voting results for the election of directors were as follows:

Director Nominee	Votes For	Votes Withheld
Yevgeny Cherny	100.00%	0.00%
Trevor Treweeke	100.00%	0.00%
Roy Ellis	100.00%	0.00%
Maxime Lemieux	100.00%	0.00%
Marc Kazimirski	100.00%	0.00%
Sheila Buck	100.00%	0.00%

Other Meeting Resolutions
Shareholders also approved the following resolutions:

Resolution	Votes For	Votes Against / Withheld
Fixing the number of directors at six	100.00%	0.00%
Appointment of SRCO Professional Corporation as auditor and authorization for the directors to fix its remuneration	100.00%	0.00%
Continuation of the existing 10% rolling stock option plan, without amendment	100.00%	0.00%

The continuation of the Company's stock option plan remains subject to acceptance by the TSX Venture Exchange.

The Company thanks its shareholders for their continued support.

About Cheelcare Inc.
Cheelcare designs and manufactures innovative mobility solutions that empower independence for people with disabilities. From the Companion power assist devices to the groundbreaking Curio robotic complex-rehab power wheelchair, Cheelcare combines engineering excellence with human-centered design to improve quality of life. For more information, please visit: www.cheelcare.ca.

For further information, please contact:
Sofiya Kagan, Director of Marketing
Cheelcare Inc.
Tel: 1-888-948-2680 x 206
Email: skagan@cheelcare.com

Forward-Looking Information:
This news release may contain forward-looking statements. Forward-looking statements are based on current expectations and involve known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those expressed or implied. Such factors include, but are not limited to, general economic conditions, market demand, supply chain disruptions, and regulatory approvals. Any forward-looking statements are made as of the date of this news release, and the Company does not undertake to update any forward-looking statements except in accordance with applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/323972

Delivra Health Issues News Release Amendment Regarding Proposed Shares for Debt Transaction

Fri, 13 Nov 2026 15:03:00 -0500

Vancouver, British Columbia--(Newsfile Corp. - November 13, 2026) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) ("Delivra Health" or the "Company"), hereby issues a correction to its news release dated November 11, 2026 (the "Prior Release") regarding a shares for payables settlement agreement to satisfy an aggregate of approximately $90,000 of the Company's outstanding payables related to services provided to the Company (the "Debt Settlement Transaction"). Subject to TSX Venture Exchange ("TSX-V") approval, the number of common shares of the Company (the "Shares") to be issued under the Debt Settlement Transaction will be 999,999 Shares at a deemed price of $0.09 per Share, rather than the 9,999,999 Shares previously reported in the Prior Release, which was a typographical error. Immediately following the Debt Settlement Transaction, the Company will have 32,261,780 Shares issued and outstanding on a non-diluted basis. All other aspects of the Prior Release are effective.

About Delivra Health Brands Inc.

Helping people take control of their health with alternative wellness solutions is what energizes the Delivra Health team! The Delivra Health portfolio features innovative brands like Dream Water™ and LivRelief™, which deliver relief from common everyday issues like chronic pain, anxiety, and sleeplessness. Delivra Health products have allowed millions of customers to reclaim their mobility, energy, and in turn, quality of life. The websites of the Company's two subsidiaries are  Dream Water™ and  LivRelief^TM. For more information, please visit  www.delivrahealthbrands.com .

Neither TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accept responsibility for the adequacy or accuracy of this release.

Investor Relations:
Jack Tasse
Chief Financial Officer
IR@delivrahealth.com
1-877-915-7934

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/323973

Dr. Amir Bajoghli Receives Top Doctor Award 2026 in Dermatology by Northern Virginia Magazine

Fri, 13 Nov 2026 14:20:00 -0500

McLean, Virginia--(Newsfile Corp. - November 13, 2026) - Dr. Amir Bajoghli of the Skin and Laser Dermatology Center has been awarded the Top Doctor in Dermatology and MOHS Surgery for 2026, by Northern Virginia Magazine. Dr. Amir Bajoghli would like to thank Northern Virginia Magazine for this honor, which he has earned for the past two decades.

This award is given to physicians and surgeons in Northern Virginia as an Official Recognition of Continued Commitment to Providing Nothing Short of Excellence.

The Northern Virginia Magazine compiles the annual Top Doctors list based on peer and panel recommendations. Nominations of doctors are based on internal evaluations, patient reviews, peer recognition, and an evaluation of the quality of care provided by the doctor.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/12317/323904_dr__amir_bajoghli_nova_2026.jpg

Dr. Bajoghli shares this honor with his dedicated staff, whose teamwork and compassion help make an exceptional patient experience possible every day. He is especially grateful to be recognized by the colleagues he works alongside and respects.

Dr. Bajoghli has been active in the field of dermatology, Mohs micrographic surgery, and cosmetic services for over twenty years. He regularly presents lectures to other physicians regionally and internationally, and teaches medical students and dermatology residents at Georgetown University School of Medicine.

Dr. Amir Bajoghli has been named Top Dermatologist and MOHS Surgeon in the Washington area by both the Washingtonian and Northern Virginia magazines in the past.

Dr. Amir Bajoghli can be reached at either of his Virginia offices:

McLean:
1359 Beverly Rd., 2nd Floor
McLean, VA 22101
(703) 893-1114

Woodbridge:
2200 Opitz Blvd., Suite 100
Woodbridge, VA 22191
(703) 492-4140

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/323904

Custom Health Closes Public Offering

Fri, 13 Nov 2026 11:48:00 -0500

Kelowna, British Columbia--(Newsfile Corp. - November 13, 2026) - Custom Health Holdings Inc. (TSX: CHLT) ("Custom Health" or the "Company"), a digital health company that helps patients manage medications and chronic conditions through in-home dispensing technology, remote monitoring and pharmacist-led care, is pleased to announce that the Company has closed its previously announced public offering (the "Offering") of units of the Company ("Units"). Pursuant to the Offering, the Company issued 2,088,514 Units at a price per Unit of $4.95 for aggregate gross proceeds of $10,338,144.30. Each Unit consists of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant"). Each Warrant entitles the holder thereof to purchase one Common Share at an exercise price of C$5.90 for a period of 60 months. The Offering was completed through Stifel Nicolaus Canada Inc., as lead agent and sole bookrunner (the "Agent").

The Units were offered in all provinces and territories of Canada other than Quebec pursuant to a prospectus supplement (the "Prospectus Supplement") dated November 11, 2026 pursuant to the Company's short form base shelf prospectus (the "Base Shelf Prospectus") dated November 5, 2026.

The net proceeds of the Offering will be used to fund the Company's initiatives, including to fund payments in relation to previously announced acquisitions and associated transaction costs, to fund planned debt repayments, general and administrative expenses and working capital all as further described in and subject to the Prospectus Supplement.

The Agent also offered the Units in the United States or to, or for the account or benefit of, a "U.S. person" (as defined in Regulation S under the United States Securities Act of 1933, as amended (the "1933 Act")) on a private placement basis to "accredited investors" (as defined in Rule 501 of Regulation D under the 1933 Act) and to "qualified institutional buyers" (as defined in Rule 144A under the 1933 Act) who are also "accredited investors", in each case pursuant to an applicable exemption from registration offered by Rule 506(b) of Regulation D and/or Section 4(a)(2) under the 1933 Act and in compliance with applicable state securities laws.

Shane Bishop, Chief Executive Officer and director of the Company, participated in the Offering by acquiring 282,830 Units for an aggregate gross purchase price of $1,400,008.50. Mr. Bishop's participation in the Offering constituted a "related party transaction" as defined under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as neither the fair market value of the securities issued to, nor the consideration to be paid by, Mr. Bishop exceeded 25% of the Company's market capitalization, as determined in accordance with MI 61-101. Further details regarding any insider participation will be included in the Company's material change report to be filed in connection with the Offering. The material change report will be filed less than 21 days before the closing date of the Offering, which the Company considers reasonable in the circumstances in order to complete the Offering in a timely manner.

The Common Shares comprising the Units have been listed on the Toronto Stock Exchange (the "TSX"), and the Common Shares underlying the Warrants and the warrants issued to the Agent have been conditionally approved for listing on the TSX. The Company will use best efforts to list the Warrants on the TSX at a later date subject to TSX approval and compliance with TSX policies; however, there is no guarantee that any such listing will occur or the timing of such listing.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Units, Common Shares and Warrants have not been and will not be registered under the 1933 Act or any state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from such registration requirements.

Copies of the Prospectus Supplement and Base Shelf Prospectus are available under the Company's profile on SEDAR+ at www.sedarplus.ca. Alternatively, the Prospectus Supplement and the Base Shelf Prospectus may be obtained free of charge upon request by contacting the Company at 1631 Dickson Ave, Suite 900, Kelowna, BC V1Y 0B5, or by email at ir@customhealth.com.

About Custom Health

Custom Health is an AI-enabled healthcare technology company that is building the infrastructure for medication management at home. The Company connects in-home technology, pharmacy and pharmacist-led clinicians to create continuous visibility into a patient's medication use and support timely clinical action. Powered by the proprietary AdhereNet® platform, Custom Health operates an integrated pharmacy network across Canada and the U.S. as part of its broader infrastructure, supporting medication delivery, medication-use insights, and pharmacist-led care to enable earlier intervention and better medication management at home. To learn more, visit customhealth.com.

For further information, please contact:

Custom Health Inquiries: info@customhealth.com, http://www.customhealth.com

Investor Relations: Pardeep Sangha, 604-572-6392, ir@customhealth.com

Cautionary Note Regarding Forward-Looking Information
Certain information in this news release constitutes "forward-looking information" within the meaning of applicable Canadian securities laws ("forward-looking statements"), including statements regarding the intended use of the net proceeds of the Offering, the listing of the Warrants, and the Company's working capital and liquidity following the Offering. Forward-looking statements can often be identified by words such as "will", "intends", "expects", "anticipates", "plans", "proposed", "may", "would", "could", "subject to" and similar expressions. These statements are based on assumptions management considered reasonable at the date they were made, that the net proceeds will be applied as described in the Prospectus Supplement, that the Company will continue to have access to its credit facilities and revenue streams as anticipated, and that there will be no material adverse change in the Company's business or in market conditions. Forward-looking statements are subject to known and unknown risks and uncertainties, including: the Company's negative working capital and the existence of material uncertainties that may cast significant doubt on its ability to continue as a going concern; the Company's undertaking to the securities regulatory authorities in connection with the Base Shelf Prospectus; reliance on credit facilities, including facilities provided by an insider of the Company and amounts available at the lender's discretion; outstanding indebtedness, including the matured promissory notes; management's discretion in the use of proceeds; dilution to existing shareholders; failure to obtain TSX approvals; the regulation of pharmacy and healthcare operations in the United States and Canada; risks associated with being a newly listed issuer; and access to additional capital. Additional risks are described under "Risk Factors" in the Base Shelf Prospectus, the Prospectus Supplement, the Company's annual information form for the fiscal year ended December 31, 2025, and the Company's amended and restated management's discussion and analysis for the period ended June 30, 2026, available on SEDAR+ at www.sedarplus.ca. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those expected. Readers are cautioned not to place undue reliance on forward-looking statements. All subsequent forward-looking statements, whether written or oral, attributable to Custom Health or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. The forward-looking statements contained in this news release are made as at the date of this news release, and the Company does not undertake any obligation to update publicly or to revise any of the forward-looking statements made herein, whether as a result of new information, future events or otherwise, except as may be required by applicable securities law.

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/323891

Vesalius Longevity Labs Appoints Harvey Spevak as Chairman to Accelerate Global Growth and Brand Development

Fri, 13 Nov 2026 07:00:00 -0500

Appointment Follows US$6.5 Million Strategic Financing and Strengthens Board Leadership Alongside David Adelman, Kevin Mayer, Lee Applbaum and James McRoberts

Vancouver, British Columbia and Scottsdale, Arizona--(Newsfile Corp. - November 13, 2026) - Vesalius Longevity Labs Inc. (CSE: VLAB)("Vesalius" or the "Company"), a leading global peptide and longevity company, today announced the appointment of Harvey Spevak, as Chairman of its Board of Directors, effective November 13, 2026. The appointment follows a US$6.5 million financing led by Mr. Spevak, who brings a globally recognized leader in the wellness space to Vesalius as interest in longevity and proactive health continues to accelerate.

Mr. Spevak is an investor, a visionary leader in global wellness, lifestyle and hospitality, and Chairman of Equinox Group. With more than three decades of experience building and scaling iconic consumer brands, he is recognized for his brand-focused, consumer-centric approach to innovation, growth and long-term value creation. As Chairman, he will help guide Vesalius' strategic direction, brand development and global expansion at the intersection of healthcare delivery and longevity science.

Vesalius supplies peptide products to a significant network of healthcare providers across key global markets supporting their practices with product fulfillment and provider education. Continuing to scale its provider-led platform globally, the Company enters this next phase with momentum as the broader peptide therapeutics market is projected to reach US$295 billion by 2033, up from US$141 billion in 2025, according to Grand View Research.

Recently, the Company announced an exclusive manufacturing partnership with FDA- registered Celularity (Nasdaq: CELU) at their Florham Park, New Jersey facility. Celularity operates a cGMP, Grade D/ISO 8, AABB certified manufacturing facility. The Company has now established an active, first-of-its-kind, U.S. "Made-in-the-USA" peptide manufacturing for its Peptual®-branded APIs (excluding any GLP type products).

"I believe longevity represents one of the most exciting opportunities in health and wellness over the coming decade," said Harvey Spevak, Chairman of Vesalius. "Vesalius has an ambitious vision for building a differentiated global platform. I'm excited to work with the Board and management team, bringing my experience in building consumer-focused brands, driving innovation and creating long-term value to help shape the company's next phase of growth."

Mr. Spevak joins fellow board members with expertise in health, finance, media and global consumer businesses including: David Adelman, Co-Owner of the Philadelphia 76ers and New Jersey Devils; Kevin Mayer, Executive Chairman and Founder of Smash Capital, Co-CEO of Candle Media and former CEO of TikTok, who led Disney+, Hulu and ESPN+ at The Walt Disney Company; Lee Applbaum, Chief Marketing Officer of Norwegian Cruise Line and former Global CMO of Patrón Spirits; Dr. Kevin Serre, PhD, formerly the Head of Performance for the Canadian Department of Defense (DoD) Special Forces under CANSOFCOM, and James McRoberts, founder of the Company & Executive Chairman of MuseCell Innovations PTE LTD.

"On behalf of the Board, I am pleased to welcome Harvey as Chairman," said David Adelman, Director of Vesalius. "He joins a group of directors whose experience across health, finance, media and consumer brands has already helped shape Vesalius into the company it is today. With Harvey leading the Board, we are well positioned as Vesalius scales globally."

"Vesalius is well positioned to help shape the future of peptides and longevity, with high-quality products, a growing provider network and significant opportunity to scale," said Kevin Mayer, Director of Vesalius. "Our ambition is to build a category-defining brand that earns the trust of providers and patients alike. I have known Harvey for many years, his leadership and strategic vision are exceptionally strong. Harvey has a proven track record of building an iconic brand and transforming an industry, and his leadership will be invaluable as we realize Vesalius' full potential."

Financial Advisor

Roth Capital Partners serves as the exclusive financial advisor to Vesalius Longevity Labs.

About Vesalius

Vesalius Longevity Labs (CSE: VLAB) is a longevity and regenerative health platform focused on peptides, biologics and preventative healthcare. Vesalius' proprietary ecosystem is designed to connect healthcare providers with trusted, compliant pharmacies and support the people they serve with access to quality therapies, education, and partnerships.

Through its announced collaboration with Celularity, the Company is developing a U.S. final-stage manufacturing and supply platform for its Peptual®-branded peptide APIs (active pharmaceutical ingredients) for domestic and international compounding supply chains in accordance with local laws and regulations. Vesalius's vision is to deliver on the promise of longevity by enabling the future of personalized health and wellness.

Investors interested in learning more about Vesalius Longevity Labs are encouraged to contact the Company at:

https://www.vesaliuslabs.com/

For further information, please refer to the Company's disclosure record on SEDAR+ at www.sedarplus.ca.

Investor contact:

Julia Becker
Vice President, Capital Markets
+1(604) 785-0850
jbecker@vesaliuslabs.com

Media contact: Jack Taylor Worldwide, vesalius@jacktaylorpr.com

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.

FORWARD-LOOKING INFORMATION

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation, including, without limitation, statements relating to: the Company's global expansion plans and growth objectives; the advancement of Vesalius' healthcare provider platform in the longevity space; the anticipated benefits of Harvey Spevak's appointment as Chairman and his expected contributions to the Company's growth and brand-building strategy; the Company's intention to leverage Mr. Spevak's expertise in scaling premium wellness experiences; the scaling of the Company's provider-led platform globally; the projected growth of the broader peptide therapeutics market, including projected market size of US$295 billion by 2033; the anticipated benefits of the exclusive manufacturing partnership with Celularity, Inc., including the development of a dedicated U.S. final stage API manufacturing and supply platform for the Company's Peptual®-branded APIs; the advancement and commercialization of the Company's Peptual®-branded peptide APIs; the Company's ambition to build a category-defining brand that earns the trust of providers and patients; and the Company's ability to shape the future of peptides and longevity.

Forward-looking information is based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Forward-looking information involves known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such risks and uncertainties include, but are not limited to: the ability of the Company to successfully execute its global expansion strategy; the ability to retain and attract key personnel, including the anticipated contributions of Mr. Spevak; the ability of the Company to grow its healthcare provider network domestically and internationally; risks associated with the manufacturing partnership with Celularity, Inc., including regulatory approvals and manufacturing timelines; the ability of the Company to successfully develop and commercialize its Peptual®-branded APIs to cGMP standards; risks inherent in the biotechnology, pharmaceutical and wellness industries, including regulatory and competitive risks; the actual size and growth rate of the peptide therapeutics market differing materially from third-party projections; the Company's ability to raise sufficient capital to fund its operations and growth plans; general economic and market conditions; and other risks described from time to time in the Company's filings made available on SEDAR+ at www.sedarplus.ca.

Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. The forward-looking information contained in this press release is expressly qualified in its entirety by this cautionary statement. The forward-looking information contained herein is made as of the date of this press release, and the Company does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/323851

Custom Health Announces Filing of Prospectus Supplement

Thu, 12 Nov 2026 23:30:00 -0500

Final Short Form Base Shelf Prospectus And Prospectus Supplement Are Accessible on SEDAR+

Kelowna, British Columbia--(Newsfile Corp. - November 12, 2026) - Custom Health Holdings Inc. (TSX: CHLT) ("Custom Health" or the "Company"), a digital health company that helps patients manage medications and chronic conditions through in-home dispensing technology, remote monitoring and pharmacist-led care, is pleased to announce that further to its press release dated November 10, 2026, the Company has filed a prospectus supplement (the "Prospectus Supplement") dated November 11, 2026, to its short form base shelf prospectus (the "Base Shelf Prospectus") dated November 5, 2026, with the securities regulatory authorities in each of the provinces and territories of Canada other than Quebec to qualify the public distribution of up to 2,424,300 units (the "Units") of the Company at a price of C$4.95 per Unit for aggregate gross proceeds of up to C$12,000,285 (the "Offering").

Each Unit will consist of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant"). Each Warrant will entitle the holder thereof to purchase one Common Share at an exercise price of C$5.90 at any time up to 60 months following the Closing Date (as defined below).

Stifel Nicolaus Canada Inc. is acting as sole agent and sole bookrunner (the "Agent") in respect of the Offering and has entered into an agency agreement dated November 11, 2026 with the Company with respect thereto. The Company also granted the Agent an option, exercisable in whole or in part at any time up to 24 hours prior to the closing of the Offering, to offer and sell up to such number of additional Units as is equal to 15% of the number of Units sold under the Offering, to cover over-allotments, if any (the "Agent's Option"). The Agent did not exercise the Agent's Option.

The full particulars of the Offering are set out in the Prospectus Supplement.

The Offering is scheduled to close on or about November 13, 2026 (the "Closing Date"). The completion of the Offering is subject to certain conditions including, but not limited to, the receipt of all necessary approvals including the approval of the Toronto Stock Exchange and the securities regulatory authorities.

Access to the Base Shelf Prospectus, the Prospectus Supplement and any amendment to the documents is provided in accordance with securities legislation relating to procedures for providing access to a shelf prospectus supplement, a base shelf prospectus and any amendment. The Prospectus Supplement, the Base Shelf Prospectus, and any amendment, as applicable, are accessible under the Company's profile on SEDAR+ at www.sedarplus.ca. An electronic or paper copy of the Base Shelf Prospectus, the Prospectus Supplement and any amendment to the documents may be obtained, without charge, from Stifel Nicolaus Canada Inc. at ECMCanada@stifel.com by providing the contact with an email address or address, as applicable. Prospective investors should read the Prospectus Supplement and the Base Shelf Prospectus, including the documents incorporated by reference therein, before making an investment decision.

It is anticipated that certain insiders of the Company may participate in the Offering. Any participation by insiders of the Company in the Offering would constitute a "related party transaction" as defined under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company expects to rely on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, as neither the fair market value of the securities to be issued to, nor the consideration to be paid by, such insiders is expected to exceed 25% of the Company's market capitalization, as determined in accordance with MI 61-101. Further details regarding any insider participation will be included in the Company's closing news release and in the material change report to be filed in connection with the Offering. The material change report will be filed less than 21 days before the Closing Date, which the Company considers reasonable in the circumstances in order to complete the Offering in a timely manner.

The Agent may also offer the Units in the United States or to, or for the account or benefit of, a "U.S. person" (as defined in Regulation S under the United States Securities Act of 1933, as amended (the "1933 Act")) on a private placement basis to "accredited investors" (as defined in Rule 501 of Regulation D under the 1933 Act) and to "qualified institutional buyers" (as defined in Rule 144A under the 1933 Act) who are also "accredited investors", in each case pursuant to an applicable exemption from registration offered by Rule 506(b) of Regulation D and/or Section 4(a)(2) under the 1933 Act and in compliance with applicable state securities laws.

Extension to PatchRx Notes

The Company is also pleased to announce that the maturity date of the PatchRx Note and the Exit Incentive Holder Note (as such terms are defined in the Prospectus Supplement) previously due October 30, 2026 has been extended to the date that the Company raises a minimum of C$20 million in aggregate gross proceeds from public and/or private equity financings completed after September 30, 2026. Any prior default under the PatchRx Note and the Exit Incentive Holder Note has also been waived. Upon repayment of the PatchRx Note and the Exit Incentive Holder Note, an additional fee equal to 10% of the outstanding obligations of the Company thereunder shall also be due and payable.

About Custom Health

For further information, please contact:

Custom Health Inquiries: info@customhealth.com, http://www.customhealth.com

Investor Relations: Pardeep Shangha, 604-572-6392, ir@customhealth.com

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Cautionary Note Regarding Forward-Looking Information
Certain information in this news release constitutes "forward-looking information" within the meaning of applicable Canadian securities laws ("forward-looking statements"), including statements regarding the Offering, the expected closing of the Offering and the anticipated timing thereof, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the Toronto Stock Exchange, the offering of Units in the United States on a private placement basis, the intended use of the net proceeds of the Offering, and the Company's working capital and liquidity following the Offering. Forward-looking statements can often be identified by words such as "will", "intends", "expects", "anticipates", "plans", "proposed", "may", "would", "could", "subject to" and similar expressions. These statements are based on assumptions management considered reasonable at the date they were made, that the Offering will close on the anticipated terms and timing, that all required approvals will be obtained, that the net proceeds will be applied as described in the Prospectus Supplement, that the Company will continue to have access to its committed credit facilities and revenue streams as anticipated, that the Company will be able to pay and satisfy the PatchRx Note and the Exit Incentive Holder Note when due, and that there will be no material adverse change in the Company's business or in market conditions. Forward-looking statements are subject to known and unknown risks and uncertainties, including: the risk that the Offering does not close on the anticipated timeline, anticipated terms or at all; the Company's negative working capital and the existence of material uncertainties that may cast significant doubt on its ability to continue as a going concern; the Company's undertaking to the securities regulatory authorities in connection with its base shelf prospectus; reliance on committed credit facilities, including facilities provided by an insider of the Company and amounts available at the lender's discretion; outstanding indebtedness, including the PatchRx Note, the Exit Incentive Holder Note and the matured promissory notes; management's discretion in the use of proceeds; dilution to existing shareholders; the regulation of pharmacy and healthcare operations in the United States and Canada; risks associated with being a newly listed issuer; and access to additional capital. Additional risks are described under "Risk Factors" in the Base Shelf Prospectus, the Prospectus Supplement, the Company's annual information form for the fiscal year ended December 31, 2025, and the Company's amended and restated management's discussion and analysis for the period ended June 30, 2026, available on SEDAR+ at www.sedarplus.ca. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those expected. Readers are cautioned not to place undue reliance on forward-looking statements. All subsequent forward-looking statements, whether written or oral, attributable to Custom Health or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. The forward-looking statements contained in this news release are made as at the date of this news release and the Company does not undertake any obligation to update publicly or to revise any of the forward-looking statements made herein, whether as a result of new information, future events or otherwise, except as may be required by applicable securities law.

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/323877

Therma Bright Increases Non-Brokered Private Placement up to $500,000

Thu, 12 Nov 2026 20:04:00 -0500

Toronto, Ontario--(Newsfile Corp. - November 12, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma Bright" or the "Company"), a developer and investment partner specializing in advanced medical device technologies, announces that further to its news release of October 23, 2026, it has received interest above the previously announced non-brokered private placement offering of up to $420,000. Accordingly, the Company is increasing this offering such that it now proposes to sell up to 16,666,667 common shares (the "Shares") at a price of $0.03/Share for total proceeds of up to $500,000.01 (the "Offering"). In accordance with the policies of the TSX Venture Exchange ("TSXV"), the Company is relying on a minimum pricing exception to issue securities at less than $0.05 per listed security.

The proposed use of proceeds from the Offering is: (i) to pay an initial deposit in relation to the manufacturing of products ($120,000); (ii) to complete a consumer marketing analysis ($50,000); (iii) to pay persons conducting Investor Relations Activities (up to $42,000); (iv) to pay outstanding amounts owing to management for reimbursement of expenses they paid on behalf of the Company and for partial payment of outstanding accrued salaries ($40,000); and (v) to pay other outstanding debt and to fund general working capital ($248,000).

The Shares will be offered to qualified investors in reliance upon exemptions from the prospectus and registration requirements of applicable securities legislation. The Company may pay finders' fees to eligible finders in connection with the Offering, subject to compliance with applicable securities laws and the policies of the TSXV.

Directors and officers may participate in the Offering. Participation by directors and officers will constitute a "related party transaction" as defined under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions ("MI 61-101"). Such participation is expected to be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of the securities that may be acquired by the insiders, nor the consideration for the securities that will be paid by such insiders, is expected to exceed 25% of the Company's market capitalization.

All securities issued and sold under the Offering will be subject to a hold period expiring four months and one day from their date of issuance.

Completion of the Offering and the payment of any finders' fees are subject to the receipt of all necessary regulatory approvals, including the approval of the TSXV.

The securities have not been and will not be registered under the United States Securities Act of 1933, as amended, or any U.S. state securities laws, and such securities may not be offered or sold to, or for the account or benefit of, persons in the United States or U.S. persons absent registration under the U.S. Securities Act and all applicable U.S. state securities laws or compliance with the requirements of an exemption therefrom. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction.

About Therma Bright Inc.

Therma Bright is a developer and investment partner specializing in advanced diagnostic and medical device technologies. The Company's portfolio includes innovative solutions for vascular health, respiratory diagnostics, and topical treatments. Therma Bright is listed on the TSX Venture Exchange (THRM), the OTCQB (TBRIF), and the Frankfurt Stock Exchange (JNX0).

For further information, please contact:

Therma Bright Inc.
Rob Fia, CEO
rfia@thermabright.com

https://x.com/Bright_Therma

FORWARD-LOOKING STATEMENTS

Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/323864

Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2027 ended September 30, 2026 and Provides Conference Call Information

Thu, 12 Nov 2026 16:38:00 -0500

Conference Call Scheduled for Friday, November 13, 2026 at 11:30 AM EST

Northvale, New Jersey--(Newsfile Corp. - November 12, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the Second quarter of fiscal year 2027 ended September 30, 2026 ("Second Quarter").

Consolidated revenues for the three-month period ending September 30, 2026, were $40.1 million, an increase of $3.8 million or approximately 10.4% as compared to the same period of the prior fiscal year. This increase was primarily due to increased revenues from the Elite label amphetamine and naltrexone product lines, as compared to the same period of the prior fiscal year. Income from operations were $9.9 million, an increase of $1.7 million or approximately 21%, as compared to the same period of the prior fiscal year. Net income attributable to common shareholders was $17.3 million for the Second Quarter.

Conference Call Information

Elite's management will host a conference call to discuss the Second Quarter of Fiscal Year 2027 financial results and provide an update on recent business developments. Stockholder questions should be submitted to the company in advance of the call.

Date:	November 13, 2026
Time:	11:30 AM EST
Dial-in numbers:	1-800-346-7359 (domestic) 1-973-528-0008 (international)
Conference number:	98840
Questions:	dianne@elitepharma.com Financial questions by 7:00 PM EST on Thursday, November 12, 2026
Audio Replay:	https://elite.irpass.com/events_presentations

The financial statements can be viewed for Elite's Second Quarter of Fiscal Year 2027 on Form 10-Q here.

About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing, manufacturing, and distributing oral, controlled-release drug products. Elite owns multiple generic products, which it distributes nationwide under the Elite Laboratories, Inc. label. Elite operates a cGMP and DEA-registered research, development, and manufacturing facility in Northvale, NJ. For more information, visit www.elitepharma.com.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/323778